Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ranok to Start China Trial of Protein Degrader for Solid Tumors and Lymphomas

publication date: Mar 12, 2024

Ranok Therapeutics, a Hangzhou-Boston biopharma that targets protein degradation for the treatment of cancers, started a China Phase I study of RNK05047, its lead protein degrader candidate. RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader discovered by Ranok. The company already has a US-based Phase I trial of the candidate underway. The China trial will enroll Chinese patients with advanced solid tumors or lymphomas. Ranok expects to report preliminary data from the two Phase 1 studies by the end of 2024. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here